Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 4 Feb 2010 |
| Director/PDMR Shareholding | 3 Feb 2010 |
| Final Results | 2 Feb 2010 |
| Correction to Final Results for Novo Nordisk A/S | 2 Feb 2010 |
| Regulatory Approval | 26 Jan 2010 |
| Regulatory Approval | 20 Jan 2010 |
| Transaction in Own Shares | 4 Jan 2010 |
| Research Update | 30 Dec 2009 |
| Transaction in Own Shares |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 21 Dec 2009 |
| Transaction in Own Shares | 14 Dec 2009 |
| Transaction in Own Shares | 7 Dec 2009 |
| Transaction in Own Shares | 1 Dec 2009 |